Several lines of evidence link metabolic dysregulation to late-life neurodegenerative diseases. The altered glucose metabolism observed in both Alzheimer's disease (AD) and Parkinson's disease (PD), as well as their connection to type 2 diabetes, is an area of significant interest. Notably, there is an overlap in risk factors for obesity, diabetes, and neurodegenerative diseases (particularly AD and PD) such as a lack of physical activity and excessive calorie consumption. Furthermore, variants in insulin signaling pathway genes have been associated with an increased risk of PD. In AD brains, there is a decrease in the glucose transporters GLUT1 (insulin-insensitive) and GLUT3 (insulin-sensitive) and GLUT4(insulin-sensitive). Additionally, insulin deficiency promotes tau phosphorylation and the development of neurofibrillary pathology. All together supports the role of disrupted insulin signaling in neurodegenerative disease progression.
This Research Topic aims to explore the critical role of dysregulated glucose metabolism in the pathogenesis of neurodegenerative diseases. It seeks to uncover the intricate relationship between metabolic dysregulation and the development and progression of conditions like AD and PD. Additionally, this Research Topic examines recent treatment strategies targeting metabolic defects in neurodegenerative diseases.
We welcome authors to submit Original Research, Reviews, Hypothesis and Theories, Perspectives, and Opinion articles. The subtopics covered in this Research Topic include:
1. Insulin resistance and brain insulin resistance
2. Hyperglycemia and insulin resistance
3. Molecular pathways involved in insulin resistance
4. Metabolic disorders and neurodegeneration
5. Type 3 diabetes
By exploring these subtopics, researchers aim to deepen our understanding of the relationship between metabolic dysregulation and neurodegenerative diseases, ultimately paving the way for potential therapeutic interventions to mitigate disease progression and improve patient outcomes.
Several lines of evidence link metabolic dysregulation to late-life neurodegenerative diseases. The altered glucose metabolism observed in both Alzheimer's disease (AD) and Parkinson's disease (PD), as well as their connection to type 2 diabetes, is an area of significant interest. Notably, there is an overlap in risk factors for obesity, diabetes, and neurodegenerative diseases (particularly AD and PD) such as a lack of physical activity and excessive calorie consumption. Furthermore, variants in insulin signaling pathway genes have been associated with an increased risk of PD. In AD brains, there is a decrease in the glucose transporters GLUT1 (insulin-insensitive) and GLUT3 (insulin-sensitive) and GLUT4(insulin-sensitive). Additionally, insulin deficiency promotes tau phosphorylation and the development of neurofibrillary pathology. All together supports the role of disrupted insulin signaling in neurodegenerative disease progression.
This Research Topic aims to explore the critical role of dysregulated glucose metabolism in the pathogenesis of neurodegenerative diseases. It seeks to uncover the intricate relationship between metabolic dysregulation and the development and progression of conditions like AD and PD. Additionally, this Research Topic examines recent treatment strategies targeting metabolic defects in neurodegenerative diseases.
We welcome authors to submit Original Research, Reviews, Hypothesis and Theories, Perspectives, and Opinion articles. The subtopics covered in this Research Topic include:
1. Insulin resistance and brain insulin resistance
2. Hyperglycemia and insulin resistance
3. Molecular pathways involved in insulin resistance
4. Metabolic disorders and neurodegeneration
5. Type 3 diabetes
By exploring these subtopics, researchers aim to deepen our understanding of the relationship between metabolic dysregulation and neurodegenerative diseases, ultimately paving the way for potential therapeutic interventions to mitigate disease progression and improve patient outcomes.
